Skye Bioscience, Inc. (SKYE) stock
SKYENasdaqPharmaceutical PreparationsFiscal year ends December 31
$1.00−0.06 (-6.10%)
Close on Nov 17, 2026Market cap $35.42MP/E –Yield –
Skye Bioscience operating cash flow
Operating cash flow is the cash the business generates from its day-to-day operations.
Skye Bioscience's operating cash flow for the twelve months ending Jun 30, 2026 was -$38.81M. For fiscal 2025 it was -$43.06M. The highest annual figure on record is $1.93K in fiscal 2012.
Annual operating cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$43.06M | – |
| FY2024 | Dec 31, 2024 | -$25.24M | – |
| FY2023 | Dec 31, 2023 | -$13.95M | – |
| FY2022 | Dec 31, 2022 | -$12.74M | – |
| FY2021 | Dec 31, 2021 | -$6.47M | – |
| FY2020 | Dec 31, 2020 | -$6.05M | – |
| FY2019 | Dec 31, 2019 | -$6.03M | – |
| FY2018 | Dec 31, 2018 | -$3.94M | – |
| FY2017 | Dec 31, 2017 | -$3.33M | – |
| FY2016 | Dec 31, 2016 | -$3.55M | – |
| FY2015 | Dec 31, 2015 | -$3.73M | – |
| FY2013 | Oct 31, 2013 | -$14.50K | -851.8% |
| FY2012 | Oct 31, 2012 | $1.93K | – |
Quarterly operating cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$7.12M | – |
| Q1 FY2026 | Mar 31, 2026 | -$8.56M | – |
| Q4 FY2025 | Dec 31, 2025 | -$9.77M | – |
| Q3 FY2025 | Sep 30, 2025 | -$13.36M | – |
| Q2 FY2025 | Jun 30, 2025 | -$10.75M | – |
| Q1 FY2025 | Mar 31, 2025 | -$9.19M | – |
| Q4 FY2024 | Dec 31, 2024 | -$8.17M | – |
| Q3 FY2024 | Sep 30, 2024 | -$5.26M | – |
| Q2 FY2024 | Jun 30, 2024 | -$7.09M | – |
| Q1 FY2024 | Mar 31, 2024 | -$4.71M | – |
| Q4 FY2023 | Dec 31, 2023 | -$3.84M | – |
| Q3 FY2023 | Sep 30, 2023 | -$4.05M | – |
| Q2 FY2023 | Jun 30, 2023 | -$1.99M | – |
| Q1 FY2023 | Mar 31, 2023 | -$4.06M | – |
| Q4 FY2022 | Dec 31, 2022 | -$4.87M | – |
| Q3 FY2022 | Sep 30, 2022 | -$2.06M | – |
| Q2 FY2022 | Jun 30, 2022 | -$2.90M | – |
| Q1 FY2022 | Mar 31, 2022 | -$2.91M | – |
| Q4 FY2021 | Dec 31, 2021 | -$1.97M | – |
| Q3 FY2021 | Sep 30, 2021 | -$1.49M | – |
| Q2 FY2021 | Jun 30, 2021 | -$1.67M | – |
| Q1 FY2021 | Mar 31, 2021 | -$1.35M | – |
| Q4 FY2020 | Dec 31, 2020 | -$1.79M | – |
| Q3 FY2020 | Sep 30, 2020 | -$1.97M | – |
| Q2 FY2020 | Jun 30, 2020 | -$1.03M | – |
| Q1 FY2020 | Mar 31, 2020 | -$1.27M | – |
| Q4 FY2019 | Dec 31, 2019 | -$1.50M | – |
| Q3 FY2019 | Sep 30, 2019 | -$1.49M | – |
| Q2 FY2019 | Jun 30, 2019 | -$1.61M | – |
| Q1 FY2019 | Mar 31, 2019 | -$1.43M | – |
| Q4 FY2018 | Dec 31, 2018 | -$1.01M | – |
| Q3 FY2018 | Sep 30, 2018 | -$816.28K | – |
| Q2 FY2018 | Jun 30, 2018 | -$1.06M | – |
| Q1 FY2018 | Mar 31, 2018 | -$1.05M | – |
| Q4 FY2017 | Dec 31, 2017 | -$2.14M | – |
| Q3 FY2017 | Sep 30, 2017 | -$99.95K | – |
| Q2 FY2017 | Jun 30, 2017 | -$271.41K | – |
| Q1 FY2017 | Mar 31, 2017 | -$816.41K | – |
| Q4 FY2016 | Dec 31, 2016 | -$662.78K | – |
| Q3 FY2016 | Sep 30, 2016 | -$511.73K | – |
See a number that looks wrong?